Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
NCT ID: NCT00009061
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
624 participants
INTERVENTIONAL
2000-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ritonavir
Abacavir sulfate
Nelfinavir mesylate
Lamivudine
GW433908
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are at least 13 years old (consent of parent or guardian needed if under 18).
* Agree to use a proven barrier method of birth control (e.g., spermicide plus condom) during the study period (hormonal birth control will not be accepted), if able to have children.
* Have received less than 4 weeks treatment with any nucleoside reverse transcriptase inhibitor (NRTI) and have never received any nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI). Mothers who have previously received 1 dose of the NNRTI nevirapine during pregnancy for prevention of mother-to-child HIV transmission are permitted to enter the study.
* Have a viral load (amount of HIV in the blood) of 1,000 copies/ml or more.
Exclusion Criteria
* Abuse drugs or alcohol in a way that would interfere with study requirements. Patients who are stable on methadone will be considered for the study.
* Have an active/acute CDC Category C event.
* Are unable to absorb or take medicines by mouth.
* Are pregnant or breast-feeding.
* Have a serious medical condition (such as diabetes, heart problem, hepatitis) that might affect the safety of the patient.
* Have had pancreatitis or hepatitis within the last 6 months.
* Have been treated with radiation or chemotherapy within 28 days before the study drug will be taken, or will have the need for these during the study.
* Have taken drugs that affect the immune system (such as corticosteroids, interleukins, interferons) or that have anti-HIV activity (such as hydroxyurea or foscarnet) within 28 days before the study drug will be taken.
* Have received an HIV vaccine within 3 months before the study drug will be taken.
* Have received certain other drugs within 28 days before the study drug will be taken, or think that they will be needed during the study.
* Have received experimental treatments.
* Have allergies which might interfere with the study, in the opinion of the doctor.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glaxo Wellcome
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Orange County Ctr for Special Immunology
Fountain Valley, California, United States
AIDS Healthcare Foundation
Los Angeles, California, United States
LAGLC
Los Angeles, California, United States
Kaiser Hospital
Sacramento, California, United States
Park Ctr for Health / Keith Vrhel
San Diego, California, United States
AIDS Research Alliance
West Hollywood, California, United States
Dupont Circle Physicians Group
Washington D.C., District of Columbia, United States
Infectious Disease Consultants
Altamonte Springs, Florida, United States
CRI of South Florida
Coral Gables, Florida, United States
Therafirst Med Ctr
Fort Lauderdale, Florida, United States
Gary Richmond MD
Fort Lauderdale, Florida, United States
Univ of Miami Dept of Medicine
Miami, Florida, United States
Specialty Med Care Ctrs of South Florida Inc
Miami, Florida, United States
Infectious Diseases Associates
Sarasota, Florida, United States
Jeffrey Levenson
St. Petersburg, Florida, United States
Infectious Disease Research Inst
Tampa, Florida, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
Med College of Georgia
Augusta, Georgia, United States
SMO USA
Conyers, Georgia, United States
Indiana Univ Med School
Indianapolis, Indiana, United States
Brigham and Women's Hosp
Boston, Massachusetts, United States
Hawthorne Med Associates / PAACA
New Bedford, Massachusetts, United States
Abbott-Northwestern Hosp / Clinic 42
Minneapolis, Minnesota, United States
Southampton Healthcare Inc
St Louis, Missouri, United States
VAMC New Jersey Healthcare System
East Orange, New Jersey, United States
North Jersey Community Research Initiative
Newark, New Jersey, United States
SUNY / Erie County Med Ctr at Buffalo
Buffalo, New York, United States
North Shore Univ Hosp
Manhasset, New York, United States
St Lukes - Roosevelt Hosp Ctr
New York, New York, United States
Bronx Veterans Affairs Med Ctr
The Bronx, New York, United States
Univ of Cincinnati / Holmes Hosp
Cincinnati, Ohio, United States
Milton S Hershey Med Ctr
Hershey, Pennsylvania, United States
Hahnemann Univ Hosp
Philadelphia, Pennsylvania, United States
Burnside Clinic
Columbia, South Carolina, United States
Methodist Healthcare
Memphis, Tennessee, United States
Nicholas Bellos
Dallas, Texas, United States
Joseph C Gathe
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APV30002
Identifier Type: -
Identifier Source: secondary_id
316B
Identifier Type: -
Identifier Source: org_study_id